GlassScriptPhysician profile
Chris Thomas Alexander
NPI 1366763757
$15,492.86
in general payments reported to CMS, 2019-2025
40 companies · $3,513 in 2025
The $3,513 reported for 2025 was more than what 85% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,477 · 2020: $1,675 · 2021: $447 · 2022: $2,576 · 2023: $2,503 · 2024: $3,301 · 2025: $3,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,237 · Travel and Lodging: $705 · Education: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,236.77 |
| Travel and Lodging | $704.62 |
| Education | $376.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,200.97 | 2021-2025 | Minimed 780g |
| Novo Nordisk INC | $2,181.05 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $1,474.12 | 2019-2025 | Repatha, Evenity, Prolia |
| Abbott Laboratories | $1,192.47 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $866.27 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $832.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $691.66 | 2019-2023 | Farxiga |
| Corcept Therapeutics | $622.05 | 2022-2025 | Korlym |
| Abbvie INC. | $615.01 | 2019-2025 | Synthroid |
| Dexcom, INC. | $520.79 | 2020-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $506.83 | 2022-2025 | Gvoke Hypopen |
| Insulet Corporation | $495.77 | 2020-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $402.89 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $343.91 | 2022-2025 | |
| Radius Health, INC. | $343.29 | 2019-2024 | Tymlos |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $282.76 | 2022-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $261.17 | 2019-2024 | |
| Tandem Diabetes Care, INC. | $221.03 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $218.42 | 2019-2021 | |
| Ibsa Pharma INC. | $178.26 | 2019-2025 | Tirosint, Tirosint, Licart |
| Ascendis Pharma Endocrinology INC | $141.70 | 2023-2025 | Yorvipath |
| Neurocrine Biosciences, INC. | $116.55 | 2025 | |
| Amneal Pharmaceuticals LLC | $110.46 | 2022-2024 | Unithroid |
| Janssen Pharmaceuticals, INC | $97.15 | 2019-2020 | |
| Antares Pharma, INC. | $78.35 | 2024-2025 | Xyosted |
| Beta Bionics, INC. | $73.03 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ascensia Diabetes Care US INC. | $60.40 | 2022-2024 | |
| Amarin Pharma, INC. | $49.31 | 2019-2022 | |
| Kyowa Kirin, INC. | $43.13 | 2023 | Crysvita |
| Shire North American Group INC | $37.14 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $34.83 | 2024 | |
| Pfizer INC. | $34.62 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $32.43 | 2022-2023 | |
| Medtronic Minimed, INC. | $28.85 | 2019-2020 | |
| Sequel Med Tech, LLC | $23.34 | 2025 | Twiist |
| Astellas Pharma US INC | $18.37 | 2025 | Veozah |
| Acerus Pharmaceuticals Corporation | $18.04 | 2022 | |
| Glaxosmithkline, LLC. | $15.38 | 2025 | Arexvy |
| Rhythm Pharmaceuticals, INC. | $14.64 | 2025 | Imcivree |
| Rgh Enterprises LLC | $14.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.